Immunocore Holdings (IMCR) FCF Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted quarterly FCF Margin of 14.58% for Q1 2026, down 1473.0% year-on-year from 1.06% in Q1 2025, and up 57.13% on a QoQ basis from 34.01% in Q4 2025.
Immunocore Holdings (IMCR) FCF Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings (IMCR) has reported FCF Margin for 6 consecutive years, with 14.58% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin fell 1473.0% year-over-year to 14.58% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.45% (down 1525.0% YoY) and the FY2025 annual result came in at 3.76%, down 1050.0% from the prior year.
- FCF Margin rose to 14.58% in Q1 2026 per IMCR's latest filing, from 34.01% in the prior quarter.
- Over the last five years, FCF Margin for IMCR reached as high as 30.69% in Q2 2024 and fell as low as 34.01% in Q4 2025.
- A 5-year average of 2.32% and a median of 5.39% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 45041 bps — and 2023, when it sank 3708 bps.
- Year by year, FCF Margin stood at 10.64% in 2022, then plunged by 348 bps to 26.44% in 2023, then grew by 21 bps to 20.86% in 2024, then plunged by 63 bps to 34.01% in 2025, then soared by 57 bps to 14.58% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 14.58%, 34.01%, and 5.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immunocore Holdings | 1.80 Bn | 957.43 Mn | 106.24 Mn | -14.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.58% |
| Dec 31, 2025 | -34.01% |
| Sep 30, 2025 | -5.02% |
| Jun 30, 2025 | 26.08% |
| Mar 31, 2025 | 0.15% |
| Dec 31, 2024 | -20.86% |
| Sep 30, 2024 | 25.30% |
| Jun 30, 2024 | 30.69% |
| Mar 31, 2024 | -7.12% |
| Dec 31, 2023 | -26.44% |
| Sep 30, 2023 | 15.23% |
| Mar 31, 2023 | 13.79% |
| Dec 31, 2022 | 10.64% |
| Sep 30, 2022 | 18.69% |
| Dec 31, 2021 | -439.77% |